Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Elong Power Holding Limited (ELPW) is up 57% at $5.65 - Citizens, Inc. (CIA) is up 17% at $5.78 - The Oncology Institute, Inc. (TOI) is up 17% at $3.08 - Everbright Digital Holding Limited (EDHL) is up 12% at $3.89 - Universal Electronics Inc. (UEIC) is up 10% at $4.06 - Korro Bio, Inc. (KRRO) is up 9% at $12.57 - Silvaco Group, Inc. (SVCO) is up 9% at $3.60 - Clene Inc. (CLNN) is up 7% at $6.38 - AleAnna, Inc. (ANNA) is up 7% at $3.91 - Klarna Group plc (KLAR) is up 5% at $15.40 [3] Premarket Losers - KinderCare Learning Companies, Inc. (KLC) is down 32% at $2.30 - PAR Technology Corporation (PAR) is down 23% at $12.22 - EverCommerce Inc. (EVCM) is down 23% at $9.25 - SenesTech, Inc. (SNES) is down 21% at $1.78 - Once Upon A Farm, PBC (OFRM) is down 18% at $16.60 - PagerDuty, Inc. (PD) is down 12% at $6.35 - SciSparc Ltd. (SPRC) is down 10% at $4.25 - Agape ATP Corporation (ATPC) is down 9% at $5.09 - OIO Group (OIO) is down 9% at $3.28 - Lifetime Brands, Inc. (LCUT) is down 6% at $3.24 [4]

Financial Data and Key Metrics Changes - The Oncology Institute achieved a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time in its history, with total revenue for Q4 2025 reaching $142 million, a 41.6% year-over-year growth [5][20] - Adjusted EBITDA for Q4 2025 was $147,000, improving from a loss of $7.8 million in Q4 2024, marking the first profitable quarter from an adjusted EBITDA perspective as a public company [4][24] - SG&A expenses decreased by 2% year-over-year, reflecting operational efficiency, with SG&A as a percentage of revenue dropping from 24.8% to 19.7% [7][23] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, driven by improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated care model, initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 patient lives under management [5][8] - The Florida Oncology Network platform grew to approximately 207 participating providers, supporting a hybrid model of patient care [10] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform, with a focus on expanding payer partnerships and achieving sustainable profitability [11][13] - The company plans to launch a proprietary network portal in Q2 2026 to enhance provider engagement and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year positive adjusted EBITDA in 2026, driven by strong growth in the delegated capitation model [4][11] - The impact of the Inflation Reduction Act on the company's revenue is expected to be minor, with management indicating multiple strategies to offset any potential negative effects [15][16] Other Important Information - The company reduced debt on its convertible preferred note by $24 million, ending the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, enhancing the company's ability to scale and execute its growth strategy [10][12] Q&A Session Summary Question: What drove the higher dispensing revenue in the quarter? - Management attributed the strong performance to operational execution in mitigating prescription leakage and strong patient encounter growth related to capitated contracts [30][31] Question: Will the Elevance contract size double in Florida in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in Florida [34][35] Question: How are margins looking for capitated revenue? - Performance in terms of volume and medical loss ratio (MLR) is as expected, with no surprises [36] Question: Will SG&A improve in 2026? - Improvements are expected, but not to the same degree as in 2025 due to growth investments [65]

Financial Data and Key Metrics Changes - The Oncology Institute achieved its first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025, with a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time [4][5] - Total revenue for Q4 2025 was $142 million, representing a 41.6% year-over-year growth, driven by patient growth and pharmacy contributions [20] - Adjusted EBITDA was $147,000 in Q4 2025, improving from -$7.8 million in Q4 2024 [24] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, primarily due to improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated footprint by initiating 9 new capitated contracts during 2025, adding approximately 260,000 patient lives under management [5] - The partnership with Elevance Health in Florida ramped up, with approximately 70,000 lives under capitated arrangements by the end of 2025 [8] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform and expects over 80% growth in capitated revenue for 2026 [11] - The company plans to launch a proprietary new network portal in Q2 2026 to enhance engagement with providers and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow and manage industry-leading medical loss ratio (MLR) performance under its delegated capitation model [13] - The company views the potential lower rate environment for Medicare Advantage as a tailwind, as it allows for proactive engagement with payers seeking to improve care delivery [74] Other Important Information - The company reduced debt on its convertible preferred note by $24 million and ended the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, including a Chief Clinical Officer and a Chief Administrative Officer [10] Q&A Session Summary Question: What drove the higher dispensing revenue in Q4? - The strong performance was driven by operational execution in mitigating leakage of prescriptions and strong patient encounter growth related to capitated contract growth [31] Question: Will the Elevance contract double in size in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in the market [35] Question: Will there be a dip in profit margins due to ramping up capitated contracts? - A slight increase in MLR is expected for delegated contracts, but overall gross margins should not dip [44] Question: Can you provide details on the number of affiliated clinics? - The network has grown to over 200 providers in Florida, bringing the total to close to 300 combined [46] Question: What are the expectations for SG&A in 2026? - Improvements in SG&A as a percentage of revenue are expected, but not to the same degree as in 2025 due to growth investments [65]

Financial Data and Key Metrics Changes - The Oncology Institute achieved approximately 28% year-over-year revenue growth, surpassing $500 million for the first time in its history, with total revenue reaching $502.7 million in 2025 compared to $393.4 million in 2024 [5][17] - The company reported its first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025, with adjusted EBITDA of $147,000, improving from a loss of $7.8 million in Q4 2024 [4][23] - SG&A expenses decreased by 2% year-over-year, reflecting operational efficiency, with total SG&A at $28 million or 19.7% of revenue in Q4 2025, down from 24.8% in the prior year [6][22] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% from $68.7 million to $80.5 million, driven by the new delegation model in Florida [17] - Pharmacy revenue increased by 49.6% year-over-year from $179.9 million to $269.2 million, primarily due to improved prescription attachment rates [18] - Patient services revenue, including capitation and fee-for-service, totaled $59.8 million in Q4 2025, representing 42.2% of total revenue and a 19.2% increase year-over-year [20] Market Data and Key Metrics Changes - The company expanded its capitated footprint by initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 patient lives under management [5] - The partnership with Elevance Health in Florida is expected to double in size in 2026, with approximately 70,000 lives currently under capitated arrangements [8][32] - The Florida Oncology Network platform grew to approximately 207 participating providers, supporting a hybrid model of patient care [10] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform to serve more patients and payers while improving access to therapeutics and reducing financial burdens [11] - The company plans to launch a proprietary new network portal in Q2 2026 to enhance engagement with providers and improve utilization management [11] - The leadership team was strengthened with new appointments, including a Chief Clinical Officer and a Chief Administrative Officer, to support growth strategy execution [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year positive adjusted EBITDA in 2026, driven by strong growth in the delegated capitation model [4][11] - The impact of the Inflation Reduction Act on the company's revenue is expected to be minor, with multiple levers available to offset any unfavorable effects [14][15] - The company believes it is well-positioned to expand payer partnerships and deliver sustainable profitability over the long term [13] Other Important Information - The company ended 2025 with $33.6 million in cash and positive free cash flow in Q4, providing flexibility for growth [7][23] - The company expects revenue in the range of $630 million to $650 million for 2026, with approximately $150 million from capitated revenue [24] Q&A Session Summary Question: What drove the higher dispensing revenue in the quarter? - The strong performance was driven by operational execution in mitigating leakage of scripts and strong patient encounter growth related to capitated contract growth [29][30] Question: Will the Elevance contract size double in Florida in 2026? - Yes, that is the goal [32] Question: Is the Humana contract new or an expansion? - The Humana contract went effective in Q4 2025 and is a new partnership [33] Question: What is the total addressable market for Elevance or Humana? - There is significant opportunity for growth in Florida, with many multiples of current capitated revenue available [34][35] Question: How are margins looking for capitated revenue? - Performance in terms of volume and MLR is as expected, with no surprises [36] Question: Will there be a dip in profit margins due to ramping up capitated contracts? - A slightly higher MLR is expected for delegated contracts, but no dip at the aggregate level [44] Question: Can you provide details on the number of affiliated clinics? - The network is larger than previously reported, with over 200 providers in Florida, totaling close to 300 combined [46] Question: Will CAR T therapies be added to treatment offerings? - Currently, the company does not take risk on CAR T therapies due to low incidence and limited availability [47] Question: What are the expectations for SG&A in 2026? - Improvements in SG&A are expected, but not to the same degree as in 2025, as investments for growth will continue [65]

Revenue Generation and Contracts - In 2025, the company generated over 46% of its revenue from patients covered by value-based contracts, predominantly in the form of capitated contracts[34]. - More than 50% of revenue in 2025 was generated from value-based contracts where payors designated affiliated providers as their preferred oncology group[67]. - The capitation arrangements involve a fixed per member per month (PMPM) payment model, aligning provider incentives with quality and efficiency of care[63]. - The TOI PCs' revenue for 2025 included approximately 16% derived from fixed fees under capitation agreements with payors[126]. - A significant portion of Patient Services revenue is dependent on a limited number of health insurance payors, with no single non-government payor accounting for more than 10% of revenue in 2025[131]. - A significant decrease in the number of capitation or fee-for-service arrangements could adversely affect revenues and results of operations[155]. Patient Care and Services - The company focuses on delivering personalized, evidence-based care while managing costs for patients and payors[31]. - The High Value Cancer Care (HVCC) program demonstrated over 25% lower median total healthcare costs from diagnosis to death[48]. - The company aims to provide access to world-class oncology care in an affordable manner to underserved populations[36]. - The average patient rating based on over 3,500 Google reviews is 4.6 out of 5 stars, indicating high patient satisfaction[52]. - The company operates specialty and retail pharmacies across five states to fill medication orders related to oncology care[28]. Growth and Expansion - The company managed a population of approximately 2.0 million patients under value-based agreements as of December 31, 2025[25]. - The company is expanding its value-based arrangements, particularly in areas with a demand for full delegation of oncology services[35]. - The company anticipates adding more TOI PC clinics through acquisitions and de novo clinic builds, enhancing market presence and capacity[56]. - The company has a robust pipeline for acquisitions, focusing on practices aligned with its value-based care philosophy[70]. - The growth strategy relies on building or acquiring new clinics to service contracts and treat patients, which involves significant risks and uncertainties[107]. Financial Performance and Risks - The Oncology Institute incurred a net loss of $60,606,000 in 2025, with a loss from operations of $36,083,000[113]. - The company anticipates increasing expenses in the future as it invests heavily in expanding its patient base and operations[113]. - A significant portion of revenue is derived from a limited number of health insurance payors, which could impact revenue if relationships are disrupted[105]. - The company faces competition for payor relationships with other healthcare organizations, which may increase costs due to ongoing consolidation in the healthcare industry[108]. - The transition from volume to value-based reimbursement models may adversely affect operations and financial results[105]. Regulatory Compliance and Legal Risks - The company is subject to various state healthcare regulations, including California Assembly Bill 1415, which requires at least 90 days' written notice before closing certain material transactions[77]. - The company is subject to federal and state healthcare regulatory laws, including the Anti-Kickback Statute and Stark Law, which impose strict compliance requirements[78][79][80]. - The company is subject to potential legal proceedings and litigation, which could materially harm its business and results of operations[173]. - The company may face significant costs and operational disruptions due to medical malpractice claims, which could strain financial resources and harm its reputation[175]. - The company is required to comply with complex fraud, waste, and abuse laws, which could lead to federal and state audits and investigations[197]. Cybersecurity and Data Privacy - Cybersecurity incidents could compromise the confidentiality and integrity of sensitive data, potentially resulting in significant costs and reputational harm[171]. - The company experienced temporary cash flow impacts due to delays in claim submissions caused by the Change Healthcare cyberattack, but does not believe the impact was material[172]. - The company collects and processes sensitive personal information, making it subject to various federal and state privacy laws, which are rapidly evolving[203]. - Violations of HIPAA can result in significant civil and criminal penalties, as well as additional oversight obligations[205]. - The company must navigate numerous state and federal laws regarding personal information processing, which complicates compliance efforts[206]. Market and Competitive Landscape - The competitive landscape includes traditional oncology practices and specialty benefit managers, with the company distinguishing itself through its integrated value-based care approach[72]. - The healthcare industry is experiencing consolidation, leading to fewer but larger payors with significant bargaining power, which may result in declining reimbursement rates[156]. - The TOI PCs' growth strategy depends on attracting new patients and retaining existing payor contracts, facing competition from other oncology providers[121]. Tax and Financial Reporting - As of December 31, 2025, the company had federal income tax NOLs of $227,510,540 and state income tax NOLs of $220,729,030 available to offset future taxable income[214]. - The deferred tax asset associated with the company's federal and state net operating losses is fully offset by a valuation allowance, limiting its impact on the effective tax rate[214]. - Future changes in tax laws or their interpretation could adversely affect the company's business, financial condition, and results of operations[215]. Operational Challenges - The company has experienced rapid growth, which has placed significant demands on management and operational resources[111]. - Increased labor costs may not be offset by rate increases due to the fixed nature of a significant percentage of revenue[159]. - The company is substantially dependent on a single source of drug supplies, which poses risks related to supply disruptions and price increases[166]. - The company must continue to invest in information technology systems to enhance patient experience and maintain competitive advantage[170].

Core Insights - The Oncology Institute, Inc. (TOI) reported significant financial growth in Q4 2025, with consolidated revenue increasing by 41.6% to $142.0 million compared to Q4 2024, and gross profit rising by 55.2% to $22.7 million [5][31] - The company achieved a net loss of $7.5 million in Q4 2025, an improvement from a net loss of $13.2 million in the same quarter of the previous year [5][31] - For the full year 2025, TOI's consolidated revenue reached $502.7 million, a 27.8% increase from 2024, while the net loss narrowed to $60.6 million from $64.7 million [5][31] Financial Highlights - Cash flow from operations in Q4 2025 was approximately $3.2 million, attributed to disciplined working capital management and an increase in gross profit margin [5] - Adjusted EBITDA for Q4 2025 was $147 thousand, a significant recovery from a loss of $7.8 million in Q4 2024 [5][31] - As of December 31, 2025, TOI had cash and cash equivalents of $33.6 million [5][31] Operational Developments - TOI expanded its capitated footprint by initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 lives under management [5] - The company ramped up its capitation partnership with Elevance in Florida and initiated agreements with Humana and CarePlus, further expanding its payor partnerships [5] - The company operates 146 affiliated and network clinics across 17 markets, managing approximately 2.0 million lives under value-based contracts [27] Outlook for 2026 - TOI projects revenue between $630 million and $650 million for fiscal year 2026, with expected gross profit ranging from $97 million to $107 million [4][6] - The company anticipates Adjusted EBITDA to be between $(1) million and $(3) million in Q1 2026 due to seasonal factors and drug pricing increases [6] - TOI expects approximately $150 million in capitated revenue in 2026 and aims to achieve full-year positive Adjusted EBITDA [6][9]

Core Insights - The Oncology Institute, Inc. (TOI) will release its fourth quarter and full year 2025 financial results on March 12, 2026, followed by a conference call at 5:00 p.m. Eastern Time [1] Financial Results Announcement - The financial results will be announced on March 12, 2026 [1] - A conference call will take place on the same day at 5:00 p.m. Eastern Time [1] Conference Call Access - The conference call can be accessed by phone at 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2] - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13758646 [2] - The replay will be available until March 19, 2026 [2] Webcast Information - Interested parties can listen to a simultaneous webcast of the conference call via the Investor Relations section of TOI's website [3] Company Overview - The Oncology Institute, founded in 2007, specializes in value-based cancer care in community settings [4] - TOI serves approximately 1.9 million patients and offers advanced cancer care services, including clinical trials and transfusions [4] - The company employs over 180 clinicians and operates more than 100 clinics across five states [4]

Core Insights - Topicus.com Inc. reported a total revenue of €436.8 million for Q4 2025, marking a 20% increase from €364.9 million in Q4 2024, with a full-year revenue of €1,552.3 million, also a 20% increase from €1,249.9 million in 2024 [5][7] - The net income for Q4 2025 rose to €79.4 million, a 41% increase from €56.2 million in Q4 2024, while the annual net income decreased to €70.1 million, a 53% decline from €149.5 million in 2024 [6][7] - The company experienced organic growth of 4% for both the quarterly and annual periods, with acquisitions contributing significantly to revenue growth [5][6] Financial Performance - Q4 2025 total revenue was €436.8 million, up €71.9 million from Q4 2024, while annual revenue reached €1,552.3 million, an increase of €257.4 million from 2024 [5][7] - Net income for Q4 2025 was €79.4 million, translating to €0.59 per share, compared to €56.2 million (€0.40 per share) in Q4 2024 [6][7] - For the full year, net income decreased to €70.1 million (€0.50 per share) from €149.5 million (€1.11 per share) in 2024, primarily due to a €221.7 million expense related to the investment in Asseco [6][7] Cash Flow and Investments - Cash flows from operations (CFO) increased by 35% to €107.7 million in Q4 2025, and by 19% to €412.7 million for the full year [9][27] - Free cash flow available to shareholders (FCFA2S) rose by 40% to €51.2 million in Q4 2025 and by 23% to €218.7 million for the year [10][27] - The company completed acquisitions totaling €390.4 million in 2025, including a net investment in Asseco Poland S.A. of €384.9 million [7][27] Assets and Liabilities - Total assets as of December 31, 2025, were €2,513.2 million, up from €1,535.9 million in 2024, with significant increases in cash and intangible assets [17][18] - Total liabilities increased to €1,731.4 million from €1,004.5 million in 2024, reflecting higher debt levels associated with acquisitions [18][27] - Shareholders' equity rose to €781.8 million from €531.4 million in 2024, driven by retained earnings and comprehensive income [18][23]

Core Insights - The Oncology Institute, Inc. (NASDAQ: TOI) is participating in several investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders [1][3]. Company Overview - Founded in 2007, The Oncology Institute specializes in value-based cancer care, serving approximately 1.9 million patients with advanced, evidence-based treatment options [2]. - The company operates over 100 clinics and affiliate locations across five states, employing more than 180 clinicians, which positions it as a significant player in community oncology [2]. Upcoming Conferences - The company will present at the Jefferies Healthcare Services Innovation & Technology Summit on March 9, 2026, featuring CEO Dr. Daniel Virnich [3]. - Additionally, a presentation at the Leerink Global Healthcare Conference will occur on the same day, with CFO Rob Carter as the presenter [3]. - The Oppenheimer 36th Annual Healthcare MedTech & Services Conference will take place on March 16, 2026, with both Dr. Daniel Virnich and Rob Carter presenting [3].

Core Insights - The Oncology Institute, Inc. has appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026, bringing over 20 years of executive leadership experience in oncology and healthcare operations [1][2] - Tzoumakas has a notable background, including her role as CEO of VytlOne National Pharmacy Services and previous leadership at 21st Century Oncology, where she led a successful operational turnaround [1][2] - The appointment is seen as timely as TOI expands its care delivery model and pharmacy business, with Tzoumakas's experience expected to enhance access, cost management, and integrated care delivery [2] Company Overview - The Oncology Institute, founded in 2007, is a leading provider of value-based cancer care in the community setting, serving approximately 1.9 million patients [3] - TOI operates over 100 clinics and affiliate locations across five states, employing more than 180 clinicians, and is focused on advancing oncology through specialized, evidence-based care [3]